We congratulate our client, OneMedNet Corporation, on the announcement of their de-SPAC transaction with Data Knights Acquisition Corp. The transaction will result in a newly combined company named OneMedNet. Upon closing, OneMedNet will continue to be led by its CEO, Mr. Paul Casey, a 40-year public company veteran with a proven track record driving value…

NEW YORK, Jan. 13, 2022 /PRNewswire/ — Broad Capital Acquisition Corp. (NASDAQ: BRACU, the “Company”) announced today that it closed its $100 million initial public offering of 10,000,000 units at $10.00 per unit. Each unit consists of one share of common stock and one right to receive one-tenth of one share of common stock upon the consummation of…

Law360 (November 30, 2021, 3:50 PM EST) — Canna-Global Acquisition Corp., a special purpose acquisition company aiming to create a multinational cannabis operator, began trading Tuesday on the Nasdaq after raising $200 million in an initial public offering, with guidance by Rimon and underwriter’s counsel Schiff Hardin. The blank-check company, which is targeting the cannabis industry and trading…

The SEC has issued its first, much anticipated statement on the regulatory status of ICOs (Initial Coin Offerings). Click here to read our analysis of the questions the SEC answered and, perhaps more importantly, the questions that remain unresolved. Mr. Futter has more than 20 years of high tech and business experience. He represents emerging companies and their…

So how do biotech ventures govern themselves to run efficiently while complying with state corporate law statutes and state and federal securities laws and regulations imposed by stock exchanges? Frugality that is often self-imposed by scientific founders and then endorsed by the angel investors and venture capital company investors that follow sequentially tend to result…

The public securities markets and the underwriters that lead biotech companies into them dictate a common capital structure suitable for IPOs, which structure almost always deviates starkly from the capital structure of the venture at inception and during its growth phase. Startups frequently commence corporate life structured as limited liability companies with a few founders…

Mindful that this series of articles describes biotech ventures that are ripe for initial public offerings even before launching an income-producing drug product into the commercial market, the paramount objective for all such ventures is to manufacture drugs and commence marketing, sales and distribution thereof as soon as possible. As you read in the previous…

For a drug discovery start-up, patent protection of the intellectual property underlying the commercialization pursuit is critically important. If the company is a university or research institution spin-out that obtained licensed rights to intellectual property through a technology transfer, either the licensor or the licensee – as set forth in the License Agreement — must pursue…

The U.S. Food & Drug Administration regulates new drug approvals in a process that is extremely thorough, lengthy and expensive. Regulations apply to a drug candidate’s product development phase, the approval process and after approval. Failure to comply could have serious business and financial con-sequences to a biotech venture, including the FDA’s refusal to approve…

Many biotech ventures begin life as an invention conceived by a scientist/professor working in a laboratory at a federally-funded university or scientific institute. The intellectual property underlying such inventions is owned by the academic institution, a potentially valuable asset to be nurtured. Since enactment of the Bayh-Dole Act in 1980, academic institutions through their technology…